EFA6R was originally identified by immunological screening of recombinant cDNA libraries obtained from hepatocellular carcinoma samples and has since been shown to be up-regulated in colon cancer and down-regulated in breast, prostate, glioblastoma, and ovarian cancer (7, 14, 19, –, 22). Here, PSD3 is linked to ovarian carcinoma.